Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment

被引：1
|
作者：
Sim, S. H.
Park, I. H.
Jung, K. H.
Kim, S-B
Ahn, J-H
Lee, K-H
Im, S-A
Im, Y-H
Park, Y. H.
Sohn, J. H.
Kim, Y. J.
Lee, S.
Kim, H-J
Chae, Y. S.
Park, K-H
Nam, B-H
Lee, K. S.
Ro, J.
机构：
[1] Natl Canc Ctr, Goyang, South Korea
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Korea Univ, Seoul, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[8] Seoul Natl Univ, Bundang Hosp, Bundang, South Korea
[9] Chung Ang Univ, Coll Med, Seoul, South Korea
[10] Dong A Univ, Coll Med, Busan, South Korea
[11] Kyungpook Natl Univ, Coll Med, Daegu, South Korea
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-17-23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-17-23
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
    Sung Hoon Sim
    In Hae Park
    Kyung Hae Jung
    Sung-Bae Kim
    Jin-Hee Ahn
    Kyung-Hun Lee
    Seock-Ah Im
    Young-Hyuck Im
    Yeon Hee Park
    Joohyuk Sohn
    Yu Jung Kim
    Suee Lee
    Hee-Jun Kim
    Yee Soo Chae
    Kyong Hwa Park
    Byung-Ho Nam
    Keun Seok Lee
    Jungsil Ro
    [J]. British Journal of Cancer, 2019, 121 : 985 - 990
  • [2] A phase I/II study of the combination of lapatinib and oral vinorelbine in HER2 positive metastatic breast cancer
    Chen, T. W-W
    Yeh, D-C
    Chao, T-Y
    Lin, C-H
    Chow, L. W-C
    Hsieh, Y-Y
    Huang, S-M
    Cheng, A-L
    Huang, C-S
    Lu, Y-S
    [J]. CANCER RESEARCH, 2016, 76
  • [3] Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
    Sim, Sung Hoon
    Park, In Hae
    Jung, Kyung Hae
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Lee, Kyung-Hun
    Im, Seock-Ah
    Im, Young-Hyuck
    Park, Yeon Hee
    Sohn, Joohyuk
    Kim, Yu Jung
    Lee, Suee
    Kim, Hee-Jun
    Chae, Yee Soo
    Park, Kyong Hwa
    Nam, Byung-Ho
    Lee, Keun Seok
    Ro, Jungsil
    [J]. BRITISH JOURNAL OF CANCER, 2019, 121 (12) : 985 - 990
  • [4] Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
    E Brain
    N Isambert
    F Dalenc
    V Diéras
    J Bonneterre
    K Rezai
    M Jimenez
    F Mefti-Lacheraf
    E Cottura
    P Tresca
    L Vanlemmens
    C Mahier-Aït Oukhatar
    F Lokiec
    P Fumoleau
    [J]. British Journal of Cancer, 2012, 106 : 673 - 677
  • [5] Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
    Brain, E.
    Isambert, N.
    Dalenc, F.
    Dieras, V.
    Bonneterre, J.
    Rezai, K.
    Jimenez, M.
    Mefti-Lacheraf, F.
    Cottura, E.
    Tresca, P.
    Vanlemmens, L.
    Oukhatar, C. Mahier-Ait
    Lokiec, F.
    Fumoleau, P.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 673 - 677
  • [6] A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
    Chen, Tom Wei-Wu
    Yeh, Dah-Cherng
    Chao, Tsu-Yi
    Lin, Ching-Hung
    Chow, Louis Wing-Cheong
    Chang, Dwan-Ying
    Hsieh, Yao-Yu
    Huang, Shu-Min
    Cheng, Ann-Lii
    Lu, Yen-Shen
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (03) : 242 - 247
  • [7] A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
    Lim, Bora
    Murthy, Rashmi K.
    Lee, Jangsoon
    Jackson, Summer A.
    Lwase, Toshiaki
    Davis, Darren W.
    Willey, Jie S.
    Wu, Jimin
    Shen, Yu
    Tripathy, Debu
    Alvarez, Ricardo
    Ibrahim, Nuhad K.
    Brewster, Abenaa M.
    Barcenas, Carlos H.
    Brown, Powel H.
    Giordano, Sharon H.
    Moulder, Stacy L.
    Booser, Daniel J.
    Moscow, Jeffrey A.
    Piekarz, Richard
    Valero, Vicente
    Ueno, Naoto T.
    [J]. BRITISH JOURNAL OF CANCER, 2019, 120 (12) : 1105 - 1112
  • [8] A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
    Bora Lim
    Rashmi K. Murthy
    Jangsoon Lee
    Summer A. Jackson
    Toshiaki Iwase
    Darren W. Davis
    Jie S. Willey
    Jimin Wu
    Yu Shen
    Debu Tripathy
    Ricardo Alvarez
    Nuhad K. Ibrahim
    Abenaa M. Brewster
    Carlos H. Barcenas
    Powel H. Brown
    Sharon H. Giordano
    Stacy L. Moulder
    Daniel J. Booser
    Jeffrey A. Moscow
    Richard Piekarz
    Vicente Valero
    Naoto T. Ueno
    [J]. British Journal of Cancer, 2019, 120 : 1105 - 1112
  • [9] Phase II Study of Neratinib and Trastuzumab plus -oral Vinorelbine in previously treated metastatic Her2 positive Breast Cancer
    Balic, M.
    Posch, F.
    Bartsch, R.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 106 - 106
  • [10] A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.
    Crown, J. P.
    Moulton, B.
    O'Donovan, N.
    [J]. CANCER RESEARCH, 2012, 72
12345